A Phase Ⅱ Study of F520 in Patients With Urothelial Carcinoma

NCT04636515 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

80

Enrollment

INDUSTRY

Sponsor class

Conditions

Locally Advanced or Metastatic Urothelial Cell Carcinoma

Interventions

DRUG: F520

Sponsor

Shandong New Time Pharmaceutical Co., LTD